High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
复制标题
与目前的常规方法相比,靶向二代测序在临床肿瘤标本方差检测方面具有较高的性能
DOI:
10.1186/s13046-017-0591-4
复制
发表时间:
2017-09-07
期刊:
影响因子:
--
通讯作者:
Li F
中科院分区:
文献类型:
--
作者:
Su D;Zhang D;Chen K;Lu J;Wu J;Cao X;Ying L;Jin Q;Ye Y;Xie Z;Xiong L;Mao W;Li F
BackgroundNext generation sequencing (NGS) is being increasingly applied for assisting cancer molecular diagnosis. However, it is still needed to validate NGS accuracy on detection of DNA alternations based on a large number of clinical samples, especially for DNA rearrangements and copy number variations (CNVs). This study is to set up basic parameters of targeted NGS for clinical diagnosis and to understand advantage of targeted NGS in comparison with the conventional methods of molecular diagnosis.MethodsGenomic DNA from 1000 Genomes Project and DNA from cancer cell lines have been used to establish the basic parameters for targeted NGS. The following confirmation was conducted by clinical samples. The multiple variants tested by amplification-refractory mutation system (ARMS), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were evaluated by targeted NGS to determine the sensitivity. Furthermore, the multiple variants detected by targeted NGS were confirmed by current conventional methods to elucidate the specificity.ResultsAt sequencing depth of 500×, the maximal sensitivities on detecting single nucletic variances (SNVs) and small insertions/deletions (Indels) can reach 99% and 98.7% respectively, and in 20% of cancer cells, CNV detection can reach to the maximal level. The following confirmation of the sensitivity and specificity was conducted by a large cohort of clinical samples. For SNV and indel detection in clinical samples, targeted NGS can identify all hotspot mutations with 100% sensitivity and specificity. OnALKfusion detection, about 86% IHC-identified cases could be identified by targeted NGS and allALKfusion detected by targeted NGS were confirmed by IHC. ForHER2-amplification, 14HER2-amplification cases identified by target NGS were all confirmed by FISH and about 93.3% of Her-2 IHC (3+) cases were identified by targeted NGS. Finally, the targeted NGS platform developed here has accurately detectedEGFRhotspot mutations in 215 NSCLC patients.ConclusionsDNA from cancer cell lines is better than standard DNA as a reference to establish basic parameters for targeted NGS. Comparison of the conventional methods using a large cohort of patient samples confirmed the high preformance of targeted NGS on detecting DNA alterations.
登录
查看更多内容
DOI:
10.1038/nrclinonc.2016.96
发表时间:
2017-01
期刊:
Nature reviews. Clinical oncology
影响因子:
--
作者:
Lopez JS;Banerji U
通讯作者:
Banerji U
DOI:
10.1002/wsbm.1159
发表时间:
2012-07
影响因子:
7.9
作者:
Lefebvre, Celine;Rieckhof, Gabrielle;Califano, Andrea
通讯作者:
Califano, Andrea
影响因子:
4.6
作者:
Wallander, Michelle L.;Geiersbach, Katherine B.;Layfield, Lester J.
通讯作者:
Layfield, Lester J.
影响因子:
12.3
作者:
Fisher S;Barry A;Abreu J;Minie B;Nolan J;Delorey TM;Young G;Fennell TJ;Allen A;Ambrogio L;Berlin AM;Blumenstiel B;Cibulskis K;Friedrich D;Johnson R;Juhn F;Reilly B;Shammas R;Stalker J;Sykes SM;Thompson J;Walsh J;Zimmer A;Zwirko Z;Gabriel S;Nicol R;Nusbaum C
通讯作者:
Nusbaum C
影响因子:
15.8
作者:
Greulich H;Chen TH;Feng W;Jänne PA;Alvarez JV;Zappaterra M;Bulmer SE;Frank DA;Hahn WC;Sellers WR;Meyerson M
通讯作者:
Meyerson M